

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Venclexta

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

| Patient Name: | Prescriber Name: Supervising Physician: | | |
|--|--|---------------------------|--|
| | | Dhana | |
| Member/Subscriber Number: | Fax: | Phone: | |
| Date of Birth: | Office Contact: NPI: | State Lie ID: | |
| Group Number: Address: | Address: | State Lic ID: | |
| City, State ZIP: | City, State ZIP: | | |
| Primary Phone: | Specialty/facility name (if applicable) | | |
| Filliary Frione. | Specially/facility frame (ii applicable) | | |
| Drug Name and Strength: | | | |
| Directions / SIG: | | | |
| Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign. | | | |
| | | | |
| Q1. Please provide ICD code(s) for diagnosis | | | |
| Q2. What diagnosis is this drug being prescribed for? | | | |
| ☐ Chronic lymphocytic leukemia (CLL) | | | |
| ☐ Other | | | |
| Q3. If you selected "other" in question 2, please provide higher recommendation per NCCN compendia or guidely | | ent with a category 2A or | |
| Q4. Is prescribing physician a hematology or oncology spe | ecialist? | | |
| ☐ Yes ☐ No | | | |
| Q5. If indication is CLL, does the patient have 17p deletion | as detected by an FDA approved | test? | |
| ☐ Yes ☐ No | | | |
| Q6. If indication is CLL, has the patient received at least or | ne prior therapy? | | |
| ☐ Yes (Please specify previous therapy tried) | | | |
| □No | | | |



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Venclexta

Phone: 800-728-7947 Fax back to: 866-880-4532

| | Prescriber Name: | Prescriber Name | |
|--|--|-----------------|--|
| Patient Name: | Supervising Physician: | | |
| Q7. Additional Comments | | | |
| | | | |
| | | | |
| | | | |
| Prescriber Signature | Date | | |
| | and signing above, I certify that applying the standard review timefrance enrollee or the enrollee's ability to regain maximum function | me may | |
| | It in a medical necessity denial. Requesting providers may speak to the SWF o have an opportunity to help impact the decision on a request before covera | | |
| | | | |
| entity named above. The authorized recipient of this infor | belonging to the sender that is legally privileged. This information is intended only for the use of the on is prohibited from disclosing this information to any other party. If you are not the intended recipition taken in reference to the contents of this document is strictly prohibited. If you have received the | oient, you are | |

error, please notify the sender immediately to arrange for the return of this document